Compare Hims and Hers Health Inc (HIMS) vs Nvidia Corp (NVDA) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.

The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.

NVIDIA (NVDA) trades at $202.81, down 2.21% on the day, amid a neutral technical signal. The company demonstrates exceptional fundamental strength with revenue surging to $130.50B in 2025 and a net income margin of 62.97%. Recent earnings have consistently beaten expectations, and analyst consensus remains strongly bullish with a $325.86 price target, suggesting significant upside potential from current levels.

The outlook for NVDA is positive, driven by its dominant position in AI chips and robust financial performance. Key investment opportunities include sustained demand for AI infrastructure and strong profitability. Risks involve increased competition, potential peak AI spending, and market volatility. The stock presents a compelling case for growth-oriented investors despite near-term price fluctuations.